Answer
Caplacizumab (Cablivi) is licensed to treat episodes of acquired thrombotic thrombocytopenic purpura (aTTP) in adults and adolescents aged 12 years or older weighing at least 40 kg, alongside plasma exchange and immunosuppression.
Sources for this answer
- Cablivi 10 mg powder and solvent for solution for injectionSANOFI · emc · SmPC §4.1 Therapeutic Indications · Version 10Document updated
Sources checked